New UK Pathway Use Has ‘Far Exceeded Expectations’
Early/Mid-Development Stage Drugs Accounted For Most 1st-Year Requests
Oncology products accounted for the largest proportion of requests for a UK “innovation passport” last year, with a wide variety of drug sponsors deciding to use the new ILAP, according to the UK regulator, the MHRA.
